Digital repository of Slovenian research organisations

Show document
A+ | A- | SLO | ENG

Title:Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease
Authors:Kačar, Mark (Author)
Fitton, John (Author)
Gough, Andrew K (Author)
Buch, Maya H (Author)
McGonagle, Dennis (Author)
Savic, Sinisa (Author)
Tipology:1.01 - Original Scientific Article
Organisation:Logo UKPBAG - University Clinic of Respiratory and Allergic Diseases Golnik
Abstract:This clinical case series describes our experience with the use of Janus kinase 1/2 inhibitor baricitinib in two patients suffering from refractory adult-onset Still's disease (AOSD) as well as in one case suffering from AOSD-like autoinflammatory disease in the context of myelodysplastic syndrome. All patients suffered from disease nonresponsive to conventional Disease-modifying antirheumatic drugs (DMARDs) as well as biological therapies including interleukin (IL)-1 and IL-6 blockade, relying instead on high daily doses of prednisolone. We also report the first case of Pneumocystis jirovecii infection following baricitinib use.
Keywords:adult onset Still's disease -- drug therapy, ankylosing spondylitis, arthritis, antirheumatic agents, undifferentiated systemic autoinflammatory disease, disease-modifying antirheumatic drugs
Year of publishing:2020
Publisher:BMJ Publishing
Source:Velika Britanija
COBISS_ID:58397187 Link is opened in a new window
ISSN on article:2056-5933
DOI:10.1136/ rmdopen-2020-001246 Link is opened in a new window
Note:Nasl. z nasl. zaslona; Opis vira z dne 6. 4. 2021; Št. članka: e001246;
Files:.pdf PDF - Presentation file, download (321,22 KB)
URL URL - Source URL, visit
Journal:RMD open
Rights:© Author(s) (or their employer(s)) 2020.
Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:01.06.2020